Document is current

Article History

Received: 14 October 2021

Accepted: 22 November 2021

First Online: 29 November 2021

Declarations

:

: The study was approved by the appropriate institutional research ethics committees and informed consent was obtained from all individual participants included in the study.

: Informed consent was obtained from all individual participants included in the study.

: N/A

: All of the procedures performed in the study involving human participants were in accordance with the ethical standards of the relevant institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Dr. Maurice-Dror reports institutional research funding from Essa Pharma Corp. for the work under consideration. Consulting fees from Biomica and personal fees from Pfizer, MSD, BMS and Medison all outside the submitted work. Dr. Le Moigne is an employee of Essa Pharma Corp and reports ownership of Essa Pharma Corp. stocks or stock options. Dr. Vaishampayan reports grants from BMS and Merck, consulting fees from BMS, Merck, Exelixis and personal fees from Exelixis and Pfizer all outside the submitted work. Dr. Montgomery reports institutional research funding from Essa Pharma Corp. and Janssen for the work under consideration. Dr. Gordon reports institutional research funding from Essa Pharma Corp. for the work under consideration, and consulting fees from Imaging End points and Daiichi, patent with Caremission, participation in advisory boards for Tracon Pharma and Agenus and receipt of equipment/material/drugs from BMS all outside the submitted work. Dr. Hong is an Essa Pharma Corp. employee and reports ownership of Essa Pharma Corp. stocks or stock options. Dr. DiMascio reports institutional research funding from Essa Pharma Corp. for the work under consideration. Dr. Perabo reports funding from Essa Pharma Corp. for the work under consideration. Dr. Chi reports institutional research funding from Essa Pharma Corp. for the work under consideration. Consulting and Honoraria from Astellas, AstraZeneca, Daiichi Sankyo, Janssen, Novartis, Pfizer, Point Biopharma, Roche and Sanofi and research Grants (to the institutions) from Astellas, AstraZeneca, Janssen and Sanofi all outside of the submitted work.